Showing 7111-7120 of 7442 results for "".
- Outrun The Sun Campaign Launched This Monthhttps://practicaldermatology.com/news/20130502-outrun_the_sun_campaign_launched_this_month/2459552/“Outrun the Sun in May,” a month-long community outreach campaign that encourages people to be both proactive—and active—in terms of skin cancer prevention, launches this month from Outrun the Sun, Inc. Outrun the Sun is partnering with the D
- Slim Fit Lab Coats Boast New Featureshttps://practicaldermatology.com/news/20130430-slim_fit_lab_coats_boast_new_features/2459555/Medelita's line of men's and women's professional lab coats now include iPad lab coat pockets on most styles. Medelita acknowledged dermatologists' frustration with the lack of functionality in standard lab coats by enhancing its features with po
- Lambrolizumab Designated as Breakthrough Therapyhttps://practicaldermatology.com/news/20130429-lambrolizumab_designated_as_breakthrough_therapy/2459556/Merck & Co. received breakthrough therapy designation from the US Food and Drug Administration for its lambrolizumab drug as a treatment of patients with advanced melanoma. Lambrolizumab is Merck's investigational antibody therapy targeting Programm
- Me Smooth Debuts on QVChttps://practicaldermatology.com/news/20130429-me_smooth_debuts_on_qvc/2459557/Syneron Beauty Inc. introduced its new me smooth at-home professional hair removal system on QVC this week. The device includes a travel bag and an additional elos cartridge to deliver effective removal of unwanted hair for all skin tones, accordi
- Web‐Based Supply Chain Management Software Launchedhttps://practicaldermatology.com/news/20130418-webbased_supply_chain_management_software_launched/2459562/Aesyntix Health, Inc. launched the Aesyntix Inventory Management (AIM), a web‐based inventory and automated ordering system to enhance its dermatology supply chain management platform. Specifically for dermatology inventory management, AIM helps
- Promius Pharma Introduces Zenatane and “The Promius Promise”https://practicaldermatology.com/news/20130412-promius_pharma_introduces_zenatane_and_the_promius_promise/2459565/Promius Pharma, LLC announced the introduction of Zenatane (Isotretinoin) Capsules, a newly approved isotretinoin option for patients with severe, recalcitrant, nodular acne. Zenatane will be supported by The Promius Promise, a pharmacy serv
- World's Most Valuable Cosmetics Brands Revealedhttps://practicaldermatology.com/news/20130410-worlds_most_valuable_cosmetics_brands_revealed/2459566/Brand Finance released its annual study of the top 50 most valuable cosmetics brands. Despite a very slight brand value fall, Olay holds its dominant position at the top of the BrandFinance Cosmetics 50 table, with a value of US$11.7 billion. However, Olay's lead at the top has shrunk from US$4 bill
- “Dermatologist from the Heart” Program Seeks Grant Proposalshttps://practicaldermatology.com/news/20130410-dermatologist_from_the_heart_program_seeks_grant_proposals/2459567/“Dermatologist from the Heart” is a new program from La Roche-Posay that aims to support initiatives designed to enhance the quality of life for patients. The initiative will award a grant to the most compassionate project spearheaded by dermatologists that seek to enhance patients' quality of life.
- Novan Therapeutics: Nitric Oxide May Inhibit Skin Steroidogenesis Locallyhttps://practicaldermatology.com/news/20130408-novan_therapeutics_nitric_oxide_may_inhibit_skin_steroidogenesis_locally/2459571/Novan Therapeutics reports topical nitric oxide-based therapies may reduce androgen levels in the skin by locally inhibiting skin steroidogenesis. The targeted reduction of androgens in the skin could lead to first-in-class local antiandrogen products to treat acne and androgenic alopecia (male patt
- Obagi Fate Uncertain as New Details Emergehttps://practicaldermatology.com/news/20130403-obagi_fate_uncertain_as_new_details_emerge/2459573/Following a bidding war with rival Merz Pharma Group, Valeant Pharmaceuticals appears set to acquire Obagi Medical Products. Valeant's original offer came in March, when the company announced that it would acquire Obagi at $19.75 per share, in a deal worth approximately $344 million. Then, in early